Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

668

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: FTC/TDF
DRUG: F/TAF
DRUG: Allowed third antiretroviral agent
DRUG: FTC/TDF Placebo
DRUG: F/TAF Placebo

Sponsor

Gilead Sciences